{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T14:06:49Z","timestamp":1776694009261,"version":"3.51.2"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,20]]},"DOI":"10.7759\/cureus.107386","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:23:58Z","timestamp":1776691438000},"source":"Crossref","is-referenced-by-count":0,"title":["Integrative Analysis of Pharmacological and Non-pharmacological Interventions in Alzheimer\u2019s Dementia"],"prefix":"10.7759","author":[{"given":"Digantkumar","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tejas","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parag N","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Dementia: Assessment, Management and Support for People Living With Dementia and Their Carers","author":"National Institute for Health and Care Excellence (NICE)","year":"2018","unstructured":"National Institute for Health and Care Excellence (NICE). Dementia: Assessment, Management and Support for People Living With Dementia and Their Carers. National Institute for Health and Care Excellence, London, UK; 2018."},{"key":"ref2","unstructured":"World Health Organization. Risk reduction of cognitive decline and dementia. WHO guidelines. (2019). https:\/\/www.who.int\/publications\/i\/item\/risk-reduction-of-cognitive-decline-and-dementia."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01296-0","article-title":"Dementia prevention, intervention, and care: 2024 report of the Lancet Standing Commission","volume":"404","author":"Livingston G","year":"2024","unstructured":"Livingston G, Huntley J, Liu KY, et al.. Dementia prevention, intervention, and care: 2024 report of the Lancet Standing Commission. Lancet. 2024, 404:572-628. 10.1016\/S0140-6736(24)01296-0","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack CR Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, et al.. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018, 14:535-62. 10.1016\/j.jalz.2018.02.018","journal-title":"Alzheimers Dement"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup","volume":"20","author":"Jack CR Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG, et al.. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement. 2024, 20:5143-69. 10.1002\/alz.13859","journal-title":"Alzheimers Dement"},{"key":"ref6","unstructured":"Alzheimer\u2019s Association. Criteria for diagnosis and staging of Alzheimer\u2019s disease. (2024). https.\/\/www.alz.org\/research\/for_researchers\/diagnostic-criteria-guidelines."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck CH","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, et al.. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023, 388:9-21. 10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"key":"ref8","unstructured":"LEQEMBI (lecanemab). (2025). https.\/\/www.leqembi.com\/en\/leqembi-study-results?utm_source=google&utm_medium=cpc&utm_campaign=Branded%3BS%3BPH%3BBR%...."},{"key":"ref9","unstructured":"FDA to recommend additional, earlier MRI monitoring for patients with Alzheimer\u2019s disease taking Leqembi (lecanemab). (2025). https.\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-recommend-additional-earlier-mri-monitoring-patients-alzhe...."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims JR","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, et al.. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023, 330:512-27. 10.1001\/jama.2023.13239","journal-title":"JAMA"},{"key":"ref11","unstructured":"Kisunla (donanemab). (2025). https.\/\/kisunla.lilly.com\/what-is-kisunla?gclsrc=aw.ds&gad_source=1&gad_campaignid=21021503404&gbraid=0AAAAApMkganDZ-...."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of gantenerumab in early Alzheimer\u2019s disease","volume":"389","author":"Bateman RJ","year":"2023","unstructured":"Bateman RJ, Smith J, Donohue MC, et al.. Two phase 3 trials of gantenerumab in early Alzheimer\u2019s disease. N Engl J Med. 2023, 389:1862-76. 10.1056\/NEJMoa2304430","journal-title":"N Engl J Med"},{"key":"ref13","unstructured":"ADUHELM (aducanumab). (2025). https.\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761178s011lbl.pdf."},{"key":"ref14","unstructured":"American Academy of Neurology. Aducanumab resources. (2025). https.\/\/www.aan.com\/tools-resources\/aducanumab-alzheimers-drug."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003154.pub6","article-title":"Memantine for dementia","volume":"3","author":"McShane R","year":"2019","unstructured":"McShane R, Westby MJ, Roberts E, et al.. Memantine for dementia. Cochrane Database Syst Rev. 2019, 3:CD003154. 10.1002\/14651858.CD003154.pub6","journal-title":"Cochrane Database Syst Rev"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.15069","article-title":"Comparative effectiveness and safety of cognitive enhancers for treating Alzheimer\u2019s disease: systematic review and network metaanalysis","volume":"66","author":"Tricco AC","year":"2018","unstructured":"Tricco AC, Ashoor HM, Soobiah C, et al.. Comparative effectiveness and safety of cognitive enhancers for treating Alzheimer\u2019s disease: systematic review and network metaanalysis. J Am Geriatr Soc. 2018, 66:170-8. 10.1111\/jgs.15069","journal-title":"J Am Geriatr Soc"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2019.20093","article-title":"Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysis","volume":"149","author":"Glinz D","year":"2019","unstructured":"Glinz D, Gloy VL, Monsch AU, et al.. Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysis. Swiss Med Wkly. 2019, 149:w20093. 10.4414\/smw.2019.20093","journal-title":"Swiss Med Wkly"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/nep3.58","article-title":"Blood-based biomarkers of Alzheimer's disease: standardization and comprehensiveness","volume":"2","author":"Liu Y","year":"2024","unstructured":"Liu Y, Guo Y, Yu J. Blood-based biomarkers of Alzheimer's disease: standardization and comprehensiveness. Neuroprotection. 2024, 2:246-54. 10.1002\/nep3.58","journal-title":"Neuroprotection"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-66728-2","article-title":"Blood biomarkers of Alzheimer's disease and progression across different stages of cognitive decline in the community","volume":"16","author":"Valletta M","year":"2025","unstructured":"Valletta M, Vetrano DL, Gregorio C, et al.. Blood biomarkers of Alzheimer's disease and progression across different stages of cognitive decline in the community. Nat Commun. 2025, 16:10412. 10.1038\/s41467-025-66728-2","journal-title":"Nat Commun"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrleng.2025.07.004","article-title":"Blood-based biomarkers for Alzheimer's disease: positioning document and usage recommendations from the Behavioral Neurology and Dementia Study Group of the Spanish Society of Neurology","volume":"40","author":"Su\u00e1rez-Calvet M","year":"2025","unstructured":"Su\u00e1rez-Calvet M, Abdelnour C, Alcolea D, et al.. Blood-based biomarkers for Alzheimer's disease: positioning document and usage recommendations from the Behavioral Neurology and Dementia Study Group of the Spanish Society of Neurology. Neurologia (Engl Ed). 2025, 40:700-12. 10.1016\/j.nrleng.2025.07.004","journal-title":"Neurologia (Engl Ed)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005562.pub3","article-title":"Cognitive stimulation to improve cognitive functioning in people with dementia","volume":"1","author":"Woods B","year":"2023","unstructured":"Woods B, Rai HK, Elliott E, Aguirre E, Orrell M, Spector A. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database Syst Rev. 2023, 1:CD005562. 10.1002\/14651858.CD005562.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1485807","article-title":"A meta-analysis of the efficacy of physical exercise interventions on activities of daily living in patients with Alzheimer's disease","volume":"12","author":"Xiao Y","year":"2024","unstructured":"Xiao Y, Fan Y, Feng Z. A meta-analysis of the efficacy of physical exercise interventions on activities of daily living in patients with Alzheimer's disease. Front Public Health. 2024, 12:1485807. 10.3389\/fpubh.2024.1485807","journal-title":"Front Public Health"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/agm2.12256","article-title":"Physical activity interventions in older adults with a cognitive impairment: a critical review of reviews","volume":"6","author":"de Rond\u00e3o CA","year":"2023","unstructured":"de Rond\u00e3o CA, Mota MP, Esteves D. Physical activity interventions in older adults with a cognitive impairment: a critical review of reviews. Aging Med (Milton). 2023, 6:290-306. 10.1002\/agm2.12256","journal-title":"Aging Med (Milton)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003433","article-title":"Community occupational therapy for people with dementia and family carers (COTiD-UK) versus treatment as usual (Valuing Active Life in Dementia [VALID]) study: a single-blind, randomised controlled trial","volume":"18","author":"Wenborn J","year":"2021","unstructured":"Wenborn J, O'Keeffe AG, Mountain G, et al.. Community occupational therapy for people with dementia and family carers (COTiD-UK) versus treatment as usual (Valuing Active Life in Dementia [VALID]) study: a single-blind, randomised controlled trial. PLoS Med. 2021, 18:e1003433. 10.1371\/journal.pmed.1003433","journal-title":"PLoS Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262828","article-title":"Cost-utility analysis of community occupational therapy in dementia (COTiD-UK) versus usual care: results from VALID, a multi-site randomised controlled trial in the UK","volume":"17","author":"Pizzo E","year":"2022","unstructured":"Pizzo E, Wenborn J, Burgess J, et al.. Cost-utility analysis of community occupational therapy in dementia (COTiD-UK) versus usual care: results from VALID, a multi-site randomised controlled trial in the UK. PLoS One. 2022, 17:e0262828. 10.1371\/journal.pone.0262828","journal-title":"PLoS One"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2022.01.013","article-title":"Light therapy for sleep disturbances in older adults with dementia: a systematic review, meta-analysis and meta-regression","volume":"90","author":"Tan JS","year":"2022","unstructured":"Tan JS, Cheng LJ, Chan EY, Lau Y, Lau ST. Light therapy for sleep disturbances in older adults with dementia: a systematic review, meta-analysis and meta-regression. Sleep Med. 2022, 90:153-66. 10.1016\/j.sleep.2022.01.013","journal-title":"Sleep Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2952","article-title":"Phototherapy improves cognitive function in dementia: a systematic review and meta-analysis","volume":"13","author":"Lu X","year":"2023","unstructured":"Lu X, Liu C, Shao F. Phototherapy improves cognitive function in dementia: a systematic review and meta-analysis. Brain Behav. 2023, 13:e2952. 10.1002\/brb3.2952","journal-title":"Brain Behav"},{"key":"ref28","unstructured":"Cochrane. Music-based therapy may improve depressive symptoms in people with dementia. (2025). https.\/\/www.cochrane.org\/about-us\/news\/music-based-therapy-may-improve-depressive-symptoms-people-dementia."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s44220-024-00342-x","article-title":"How and why music therapy reduces distress and improves well-being in advanced dementia care: a realist review","volume":"2","author":"Thompson N","year":"2024","unstructured":"Thompson N, Odell-Miller H, Underwood BR, Wolverson E, Hsu  MH. How and why music therapy reduces distress and improves well-being in advanced dementia care: a realist review. Nat Mental Health. 2024, 2:1532-42. 10.1038\/s44220-024-00342-x","journal-title":"Nat Mental Health"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-10-200611210-00005","article-title":"Enhancing the quality of life of dementia caregivers from different ethnic or racial groups: a randomized, controlled trial","volume":"145","author":"Belle SH","year":"2006","unstructured":"Belle SH, Burgio L, Burns R, et al.. Enhancing the quality of life of dementia caregivers from different ethnic or racial groups: a randomized, controlled trial. Ann Intern Med. 2006, 145:727-38. 10.7326\/0003-4819-145-10-200611210-00005","journal-title":"Ann Intern Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.14716","article-title":"Impact of the REACH II and REACH VA dementia caregiver interventions on healthcare costs","volume":"65","author":"Nichols LO","year":"2017","unstructured":"Nichols LO, Martindale-Adams J, Zhu CW, Kaplan EK, Zuber JK, Waters TM. Impact of the REACH II and REACH VA dementia caregiver interventions on healthcare costs. J Am Geriatr Soc. 2017, 65:931-6. 10.1111\/jgs.14716","journal-title":"J Am Geriatr Soc"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h369","article-title":"Assessment and management of behavioral and psychological symptoms of dementia","volume":"350","author":"Kales HC","year":"2015","unstructured":"Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015, 350:h369. 10.1136\/bmj.h369","journal-title":"BMJ"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.3018","article-title":"Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm","volume":"72","author":"Maust DT","year":"2015","unstructured":"Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, Kales HC. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015, 72:438-45. 10.1001\/jamapsychiatry.2014.3018","journal-title":"JAMA Psychiatry"},{"key":"ref34","unstructured":"U.S. FDA. Approval and labeling resources for brexpiprazole agitation indication. (2023). https.\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/205422s009lbl.pdf."},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.173501","article-title":"The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia","volume":"173","author":"Reus VI","year":"2016","unstructured":"Reus VI, Fochtmann LJ, Eyler AE, et al.. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016, 173:543-6. 10.1176\/appi.ajp.2015.173501","journal-title":"Am J Psychiatry"},{"key":"ref36","unstructured":"FDA approves first drug to treat agitation symptoms associated with dementia due to Alzheimer\u2019s disease. (2023). https.\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-treat-agitation-symptoms-associated-demen...."},{"key":"ref37","unstructured":"REXULTI\u00ae (brexpiprazole) 2 mg\/day was superior in reducing mean MADRS total score vs antidepressant + placebo. (2023). https.\/\/www.rexultihcp.com\/mdd\/efficacy?tc=ps_ecfyqslb0r&cc=1010&utm_medium=cpc&utm_campaign=GS_BR-general-Rex+MDD-HC...."},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034634","article-title":"Trial of pimavanserin in dementia-related psychosis","volume":"385","author":"Tariot PN","year":"2021","unstructured":"Tariot PN, Cummings JL, Soto-Martin ME, et al.. Trial of pimavanserin in dementia-related psychosis. N Engl J Med. 2021, 385:309-19. 10.1056\/NEJMoa2034634","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4065","article-title":"Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial","volume":"343","author":"Husebo BS","year":"2011","unstructured":"Husebo BS, Ballard C, Sandvik R, Nilsen OB, Aarsland D. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ. 2011, 343:d4065. 10.1136\/bmj.d4065","journal-title":"BMJ"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/gps.2649","article-title":"Pain treatment of agitation in patients with dementia: a systematic review","volume":"26","author":"Husebo BS","year":"2011","unstructured":"Husebo BS, Ballard C, Aarsland D. Pain treatment of agitation in patients with dementia: a systematic review. Int J Geriatr Psychiatry. 2011, 26:1012-8. 10.1002\/gps.2649","journal-title":"Int J Geriatr Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/465344-integrative-analysis-of-pharmacological-and-non-pharmacological-interventions-in-alzheimers-dementia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:24:10Z","timestamp":1776691450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/465344-integrative-analysis-of-pharmacological-and-non-pharmacological-interventions-in-alzheimers-dementia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":40,"URL":"https:\/\/doi.org\/10.7759\/cureus.107386","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,20]]}}}